Browsing Tag
Inluriyo
4 posts
FDA approves Eli Lilly’s Inluriyo-Verzenio combination for ESR1-mutated breast cancer
The United States Food and Drug Administration has approved Inluriyo with Verzenio for a genetically defined form of advanced breast cancer after endocrine therapy. In a 159-patient analysis, median progression-free survival reached 11.1 months with the combination versus 5.5 months with Inluriyo alone, expanding Eli Lilly's ability to pair two medicines from its own oncology portfolio.
Eli Lilly’s Inluriyo and Verzenio combo data reshape outlook for ER+, HER2– metastatic breast cancer treatment
Eli Lilly’s EMBER-3 update boosts Inluriyo’s profile in breast cancer care—find out how its all-oral combo with Verzenio could shift treatment standards.
FDA approval of Eli Lilly’s Inluriyo: Can the new oral SERD reshape advanced breast cancer treatment?
FDA clears Eli Lilly’s Inluriyo for ESR1-mutated advanced breast cancer. Explore trial data, stock sentiment, pricing, and future oncology outlook.
Eli Lilly wins FDA approval for Inluriyo in ESR1-mutated metastatic breast cancer
FDA approves Eli Lilly’s Inluriyo for ESR1-mutated breast cancer, boosting oncology pipeline and investor confidence. Learn how this reshapes treatment.